Solzira NDA resubmitted
Executive Summary
GlaxoSmithKline and XenoPort resubmit their NDA for Solzira (gabapentin enacarbil) for the treatment of restless leg syndrome Jan. 9. GSK withdrew the application last November when FDA requested that data in a single study be reformatted (1"The Pink Sheet" DAILY, Nov. 10, 2008). In addition to reformatting the data, GSK also conducted a review of other clinical studies, and the filing now consists of three Phase III trials
You may also be interested in...
FDA Wants Solzira Restless Legs Data Reformatted
Filing’s content is unaffected, says GlaxoSmithKline, which withdrew the recently submitted NDA but will resubmit it “as quickly as possible.”
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.